5 89 subgroup and indeed includes the effect observed in patients with normal serum albumin.
90 Consequently, it cannot be ruled out that the effect was only not detected in the smaller 91 group, and no interaction between the treatment and albumin can be observed. A second 92 reason against claiming predictiveness based on the analysis of subgroups only is that even if 93 there are effects in both subgroups, predictiveness of the biomarker cannot be excluded, 94 because the therapeutic effect might be weaker (quantitative interaction) or in the opposite 95 direction (qualitative interaction) in the second subgroup.
96 In the following, we will describe the statistical methods to evaluate the biomarker-by-97 treatment interaction that needs to be shown for the predictiveness of a biomarker. 99 The statistical method of choice to evaluate the biomarker-by-treatment interaction 100 depends on the data, i.e., the scale of the outcome variable and additional covariables that 101 are to be included in the model. In the following, we will focus on the simple setting of a 102 dichotomous outcome without further covariables. As a first approach, a linear regression 103 framework can be used in which the risk or probability of the dichotomous outcome y (e.g. 127 this model is that the predicted outcome probability will be guaranteed to lie between 0 and 128 1. Furthermore, the logit link is the natural parameter from the linear exponential family 129 which provides excellent statistical properties.
Statistical evaluation of biomarker-by-treatment interaction
130 The linear and the logistic models are different, they have different effect sizes. This can be 131 seen from S1 Appendix in which we have derived the relation between ARRs from the linear 132 probability model and ORs from the logistic regression model. 151 showing the risk or probability of an outcome depending on the treatment and biomarker 152 status. In this example, changing the biomarker status from negative to positive always 153 increases the risk by 20%, and changing the treatment from control to experimental always 154 increases the risk by 40%. Thus, there is no additive biomarker by treatment interaction. We 155 now assume that we wish to select patients who will benefit most from the treatment. If 156 there were 100 patients each who were biomarker positive and negative, 10 and 30 would 157 reach a positive outcome, respectively, under control treatment (Fig 2A) . Switching to the 158 experimental treatment instead, the numbers could be increased to 50 and 70, respectively.
159 This means that in either biomarker group, 20 patients would benefit from the experimental 8 160 treatment, indicating that the biomarker status does not need to be taken into account 161 when offering the treatment, which is mirrored by the lack of an additive interaction.
162 Consider now the data in 197 general probability of developing the disease, the probability might be influenced by having 
233
biomarker status, respectively.
234
4. Sample the treatment success from a Bernoulli distribution using the probability from 235 formula ( 2 ) or ( 3 ).
236
We consider as prevalence for the biomarker, and we use and ∈ {0.1, 0.25, 0.5} 0 = 0 237 to simulate populations, i.e., there is no prognostic effect of the biomarker. We create = 0 238 study populations of sizes . In case of the "biomarker-stratified ∈ {100, 200, 500, 1000}
239 randomization" trial either half of the study population is biomarker positive and the other 240 half is biomarker negative; alternatively, the proportion of biomarker positive patients is 241 determined by the biomarker prevalence in the respective simulated population, i.e.
242 specifying explicitly or specifying only , and from this follows . We
243 use as randomization factors, and in the "biomarker-stratified , + , -∈ {0.25, 0.5, 0.75} 277 The code is available in the supplement (S2 Appendix).
Results
279 Table 2 shows the estimated frequency of type I errors of the interaction test, i.e., the 280 restricted deviance test, in logistic and linear regression models to detect a interaction effect 281 simulated via the linear (upper part) or logistic (lower part) model. Given are the frequencies 282 in the "randomize-all" trial design with biomarker prevalence and randomization = 0.1 283 factor for some selected effect size combinations with no ( and = 0.5 = log (1) 284 ), moderate ( or and ) and strong ( = 0 = log (1.5) = log ( (Table 5 ) is much higher than in the 360 "randomize-all" design (Table 3) . Both regression models violate the criterion in about 9% of 374 Based on the likelihood ratio-based restricted deviance test in the "biomarker-stratified" 382 assumed that out of a larger patients' group with biomarker information, only a specified 383 number is selected and included in the trial, so that there is an equal number of biomarker 384 positive and negative cases. In this situation, the estimated type I error is very close to the 385 expected in all scenarios with no interaction effect (Table 6) , even in scenario 4. 0.05 386 Remarkably, in this trial design, the lowest numbers of scenarios violating Bradley's criterion 387 of robustness is observed (Table 7 ). The logistic model violates the criterion 36 times and the 388 linear model 81 times, both about 1% of all scenarios with and fixed = = 0 + , -389 at . Unexpectedly, in this setting the linear model also tends to be liberal. 406 hard to detect, resulting in a low power. In general, however, the pattern of the estimated 407 power is very similar to before, with an overall higher power due to balanced sample sizes. 
416
417 For an overview, Table 9 shows a comparison of the estimated power across the considered 418 scenarios. Here, the number of scenarios is given in which the power in the linear and 419 logistic regression model is comparable (less than 3% difference), in which one of the models 420 is slightly better (difference between 3% and 10%), and in which one of the models is better 421 (difference greater than 10%). These numbers are given for all considered scenarios and only 422 for scenarios without extreme effect constellations. For the vast majority of scenarios, the 423 difference in estimated power of the linear and logistic model is irrelevant, i.e., the 424 difference is less than 3%, and differences are smaller with larger sample sizes. 
